The Latest Breaking News from Statera Biopharma Inc

Statera Biopharma Inc (NASDAQ:STAB) has entered into a non-binding term sheet with Immune Therapeutics Inc (OTC:IMUN) to sell its naltrexone and met-enkephalin rights. The transaction is contingent upon the negotiation of a definitive agreement and satisfaction of several closing conditions, including a contingency on Immune Therapeutics financing. Under the anticipated terms, Statera will receive an…

Coeptis Therapeutics Inc (OTC:COEP) has entered into a strategic agreement with Statera Biopharma Inc (NASDAQ:STAB) that gives Coeptis the right to acquire Statera'stoll-like receptor 5 (TLR5) agonist platform, including entolimod.  Coeptis will agree to pay Statera Biopharma $6 million and revenue-based milestone payments to be defined in the definitive agreement. TLR5 is an innate immunity…